This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Apr 2023

FF/VI is an inhaled therapy for the treatment of asthma, with a prolonged duration of antiinflammatory and bronchodilatory action.1 This study investigated the global metabolomic and lipidomic profile following treatment with FF/ VI or placebo and assessed whether changes correlated with exhaled nitric oxide levels as a measure of airway inflammation.1 Despite the prolonged airway antiinflammatory action, this study detected only a subtle systemic metabolomic and lipidomic changes with FF/VI treatment.1
 

Read more

References:

  1. Daley-Yates P et al. Respir Res 2022;23:258.

To report an Adverse Event, please contact the toll free line 0800 CALL GSK (0800 2255 475) or send an email